pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,561 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT797Endpoints599BioPharma Dive230onclive165Fierce Biotech71BioSpace69raps29
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • #ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this year
    Roche says it has one obesity drug with a potential best-in-class safety profile, and another with a similar shot at leading in efficacy. Combining them could produce a highly successful product if…
    Endpoints · 1mo ago↗ source
  • Lawmakers propose China restrictions; #ASCO26 recap; and more
    Welcome back to Endpoints Weekly! We had a small team in Chicago last weekend at this year’s ASCO conference. You’ll find a recap of their coverage below, including more details on Revolution Medic…
    Endpoints · 1mo ago↗ source
  • Opinion: How the Amish think about vaccines, health care costs, and much more
    There may be nearly 2 million Amish Americans by 2075. That has large public health implications.
    STAT
← prev
page 30 of 63
next →
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
· 1mo ago
↗ source
  • Opinion: I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous action
    “Ebola is an unforgiving enemy,” writes Tom Frieden, who led the U.S. CDC response to the 2014-2016 Ebola outbreak.
    STAT · 1mo ago↗ source
  • #ADA26: Roche's incretin shot works in mid-stage trial in type 1 diabetes
    A daily incretin shot being developed by Roche has shown promise in type 1 diabetes — the form that is not generally believed to be directly treatable by GLP-1-based drugs. According to Phase 2 d…
    Endpoints · 1mo ago↗ source
  • CDC: Ebola outbreak in Central Africa could reach 20,000 cases without strong countermeasures
    The Ebola outbreak in Central Africa could grow to 20,000 cases or more, depending on how quickly infected people are isolated to slow the spread, according to a new U.S. analysis.
    STAT · 1mo ago↗ source
  • STAT+: Newer GLP-1s, pushback on research cuts, and a protest
    You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.
    STAT · 1mo ago↗ source
  • STAT+: What stripping civil service protections for thousands of federal workers will mean for HHS
    Thousands of HHS staff who shape policy have had their employment status changed to a designation that makes it easier for them to be fired.
    STAT · 1mo ago↗ source
  • Senior NIH official pushes MAHA strategy to skeptical ADA audience
    An NIH advisor told researchers gathered at the American Diabetes Association conference that MAHA goals match the agency's priorities.
    STAT · 1mo ago↗ source
  • In Washington, biotech's China hawks are winning the conversation
    Biopharma industry lobby groups working to keep the pipeline open for plentiful, lower-cost drugs coming from China have awakened to the fact that they face a vocal opposition and a growing set of…
    Endpoints · 1mo ago↗ source
  • Industry seeks more clarity on commissioner's voucher program
    The pharma industry and rare disease advocates voiced concerns about the transparency and fairness of the Commissioner's National Priority Voucher pilot program. The program faces an uncertain fu…
    Endpoints · 1mo ago↗ source
  • House committee directs FDA to speed up IND sign-off process
    The House Appropriations Committee told the FDA to reform the way it signs off on new clinical trials, reflecting a broader effort to ensure the US keeps pace with China and other nations in develo…
    Endpoints · 1mo ago↗ source
  • Innovent declares Phase 3 success for ADC that attracted huge Takeda deal
    Innovent Biologics' ADC candidate has passed a Phase 3 trial in advanced stomach cancer and is under priority review in China, but details of the success are still under wraps. The Phase 3 win wi…
    Endpoints · 1mo ago↗ source
  • Opinion: If Americans risk their lives fighting Ebola overseas, they deserve the right to come home
    Outbreak response is difficult enough without asking responders to wonder whether they will have access to the best available care if they become ill.
    STAT · 1mo ago↗ source
  • STAT+: Will Makary’s FDA voucher program survive?
    RevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news
    STAT · 1mo ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    STAT · 1mo ago↗ source
  • Texas AG investigating energy drinks
    The limitations of private health insurance, the quiet collapse of America's research ethics watchdog and other Morning Rounds news
    STAT · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about Roche accusing U.S. of ‘blackmail,’ a ruling on skinny labels, and more
    Drugmakers and patient groups asked the FDA to pause former commissioner Marty Markary's National Priority Voucher drug review program
    STAT · 1mo ago↗ source
  • Fulcrum lays off majority of staff; Seres extends runway into 2027
    👥 Fulcrum Therapeutics reduced to a shell: The biotech is letting go 48 of its 57 full-time employees, according to an SEC filing. The step comes after Fulcrum said
    Endpoints · 1mo ago↗ source
  • Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec
    Uli Stilz has been trotting the globe this year to talk about the future of biotech and bridge an increasingly international industry. He was in Japan this week,
    Endpoints · 1mo ago↗ source
  • Opinion: How living and practicing medicine abroad complicated my beliefs about universal health care systems
    “I believe deeply in universal health care. But universal care must also mean universal safety and accountability, not merely universal access.”
    STAT · 1mo ago↗ source
  • Tiny HHS office tasked with protecting research participants’ safety is running on fumes
    OHRP has experienced an unprecedented exodus of ethics expertise, raising concerns about its ability to effectively protect volunteers.
    STAT · 1mo ago↗ source
  • HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapy
    Americans who have high-risk exposures to Ebola in the current outbreak in Central Africa will have access to an experimental antibody treatment.
    STAT · 1mo ago↗ source
  • Otsuka touts new IgAN evidence as it seeks full approval for Voyxact
    Otsuka Pharmaceutical reported new evidence on Thursday that it thinks will help support a full approval for its monoclonal antibody Voyxact in a chronic autoimmune disease that affects the kidneys…
    Endpoints · 1mo ago↗ source
  • STAT+: Drug companies, patient groups urge FDA to pause commissioner’s voucher program
    The White House has used the program to reward companies that help its political goals.
    STAT · 1mo ago↗ source